Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,921,754
  • Shares Outstanding, K 22,711
  • Annual Sales, $ 180,130 K
  • Annual Income, $ -465,890 K
  • EBIT $ -307 M
  • EBITDA $ -305 M
  • 60-Month Beta -1.01
  • Price/Sales 13.06
  • Price/Cash Flow N/A
  • Price/Book 17.84

Options Overview Details

View History
  • Implied Volatility 49.39% (+0.10%)
  • Historical Volatility 49.64%
  • IV Percentile 17%
  • IV Rank 22.83%
  • IV High 82.86% on 04/08/25
  • IV Low 39.49% on 08/15/25
  • Expected Move (DTE 28) 39.12 (8.99%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 838
  • Volume Avg (30-Day) 445
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 12,990
  • Open Int (30-Day) 11,009
  • Expected Range 395.89 to 474.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.35
  • Number of Estimates 3
  • High Estimate 3.02
  • Low Estimate -1.09
  • Prior Year -3.32
  • Growth Rate Est. (year over year) +110.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
424.48 +2.48%
on 02/20/26
506.39 -14.10%
on 01/28/26
-69.94 (-13.85%)
since 01/20/26
3-Month
424.48 +2.48%
on 02/20/26
615.00 -29.27%
on 12/24/25
-107.11 (-19.76%)
since 11/20/25
52-Week
265.00 +64.15%
on 05/27/25
615.00 -29.27%
on 12/24/25
+83.98 (+23.92%)
since 02/20/25

Most Recent Stories

More News
Madrigal: Q4 Earnings Snapshot

Madrigal: Q4 Earnings Snapshot

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra ...

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 435.01 (-0.43%)
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

SUZHOU, China and MÖLNDAL, Sweden , Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced...

MDGL : 435.01 (-0.43%)
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational...

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday,...

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 435.01 (-0.43%)
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 435.01 (-0.43%)
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapies DGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra ® (resmetirom)...

MDGL : 435.01 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 470.94
2nd Resistance Point 459.55
1st Resistance Point 447.28
Last Price 435.01
1st Support Level 423.61
2nd Support Level 412.22
3rd Support Level 399.95

See More

52-Week High 615.00
Fibonacci 61.8% 481.30
Fibonacci 50% 440.00
Last Price 435.01
Fibonacci 38.2% 398.70
52-Week Low 265.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar